BC Week In Review | Oct 19, 2015
Company News

Inhibrx, Alpha-1 Foundation deal

Inhibrx and Alpha-1’s Alpha-1 Project Inc. subsidiary partnered to develop a recombinant alpha-1 antitrypsin (AAT) therapeutic. Alpha-1 will make an undisclosed equity investment in Inhibrx, which is developing AAT-Fc . The recombinant AAT ( A1AT ; SERPINA1...
Items per page:
1 - 1 of 1